Bristol-Myers Squibb Appoints Frances Heller Senior Vice President, Business Development

Bristol-Myers Squibb Appoints Frances Heller Senior Vice President, Business Development

Friday, September 28, 2012 4:32 pm EDT

NEW YORK----Bristol-Myers Squibb Company (NYSE: BMY) today announced that Frances Heller will join the company as senior vice president, Business Development, on October 1, 2012. She will report to Lamberto Andreotti, chief executive officer, and will be a member of the company's Senior Management Team.

"With broad experience across both the biotech and pharmaceutical industries, I believe Fran will be an important addition to my diverse management team and to the company," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "In addition, her scientific, business and legal background, as well as her experience across therapeutic areas, will help Bristol-Myers Squibb continue to execute its strategy of finding external innovation that complements our own internal R&D pipeline and helps us bring important new medicines to patients."

Prior to joining Bristol-Myers Squibb, Ms. Heller was executive vice president, Business Development at Exelixis, where she accomplished several large, company-transforming transactions. Prior to that, Ms. Heller was head of Strategic Alliances at Novartis Pharmaceuticals where she was responsible for transactions with partners in the pharmaceutical and biotech industry as well as academic institutions worldwide. Previously, she was Corporate and Intellectual Property counsel for Celera Genomics. Ms. Heller serves on the board of directors of several biotech companies and universities, is a Trustee at the Dana Farber Cancer Institute and teaches a business class at Stanford University on the biotech and pharmaceutical industry.

"I am excited by the opportunity to join Bristol-Myers Squibb and its Senior Management Team," said Ms. Heller. "Bristol-Myers Squibb is well known and respected for integrating business development as a key component of its strategy. I am looking forward to joining a team that is committed to continuing to build a differentiated capability in evaluating, securing and maintaining innovative transactions."

Ms. Heller is a member of the California State Bar, is licensed by the U.S. Patent and Trademark Office, and has a B.S. in biology from Tulane University, an M.A. in biology from American University, and a J.D. from Golden Gate University School of Law.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at


Bristol-Myers Squibb
Jennifer Fron Mauer, 609-252-6579
[email protected]
John Elicker, 609-252-4611
[email protected]

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.